We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0QXX market cap is 916.12M. The company's latest EPS is CHF -1.7050 and P/E is -14.78.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Revenue | 20.38M | 9.34M | 9.33M | 189.56M | 7.04M |
| Operating Income | -36.66M | -58.33M | -63.42M | 116.61M | -61.11M |
| Net Income | -36.29M | -62.76M | -63.79M | 117.85M | -61.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Assets | 104.94M | 187.55M | 172.67M | 262.26M | 198.35M |
| Total Liabilities | 50.8M | 80.33M | 65.38M | 27.09M | 21.92M |
| Total Equity | 54.14M | 107.22M | 107.29M | 235.17M | 176.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Operating | -1.19M | -28.98M | -90.95M | 118.57M | -59.01M |
| Investing | -19.84M | -21.75M | -22.24M | -101.12M | 44.64M |
| Financing | -227k | 113.2M | 50.58M | -1.57M | -1.17M |
| Market Cap | 916.12M |
| Price to Earnings Ratio | -14.78 |
| Price to Sales Ratio | 130.17 |
| Price to Cash Ratio | 13.61 |
| Price to Book Ratio | 5.19 |
| Dividend Yield | - |
| Shares Outstanding | 36.35M |
| Average Volume (1 week) | 775 |
| Average Volume (1 Month) | 820 |
| 52 Week Change | 0.00% |
| 52 Week High | 25.20 |
| 52 Week Low | 25.20 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Molecular Partners Ag |
| Address |
wagistrasse 14 schlieren 8952 |
| Website | https://www.molecularpartners.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
